Gilead to acquire global rights of Trodelvy from Everest
Under the deal, Gilead has a chance to hire Everest staff working on the Trodelvy programme.

Under the deal, Gilead has a chance to hire Everest staff working on the Trodelvy programme.
The companies will expedite the stockpiling, channel distribution and offer access to hospitals for the antibody therapy.
In a Phase III trial, the antibody combination offered a statistically significant 80% decline in hospitalisation and death.
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
Four programmes of F-star are currently in the clinic while various other undisclosed programmes are in the developmental stage.
The approval is based on clinical data from the Phase III RATIONALE 309 clinical trial of tislelizumab plus chemotherapy.
In a Phase IIb trial in 80 subjects, Trodelvy offered an overall response rate of 38.8%.
The vaccine is intended for active immunisation against polioviruses Type 1, 2, and 3 in infants.
Thank you for subscribing to Pharmaceutical Technology